View source for LBF16000PG02

{{Lipid/Header}}

{{Hierarchy|{{PAGENAME}}}}

{{Metabolite
|LipidBank=XPR1521
|LipidMaps=LMFA03010139
|SysName=8- [ 2 (R) - (2-Carboxyethyl) -3 (S) ,5 (R) -dihydroxycyclopentan-1 (R) -yl ] -6-oxooctanoic acid
|Common Name=&&8- [ 2 (R) - (2-Carboxyethyl) -3 (S) ,5 (R) -dihydroxycyclopentan-1 (R) -yl ] -6-oxooctanoic acid&&
|Mass Spectra=DIMETHYL ESTER DI-TMS ETHER ; m/e 502(M^+ ), 487, 412, 397, 325, 322, 291, 254, 241, 228, 217, 191, 179, 143 [[Reference:Granstrom_E:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,3398|{{RelationTable/GetFirstAuthor|Reference:Granstrom_E:Samuelsson_B:,J. Am. Chem. Soc.,1969,91,3398}}]]
|Source=When prostaglandin F2alpha was administered intravenously to female subjects, 5alpha,7alpha-dihydroxy-11-keto-tetranor-prosta-1,16-dioic acid was found as a major urinary metabolite (PGFalpha-MUM) [[Reference:Granstrom_E:Samuelsson_B:,J. Biol. Chem.,1971,246,5254|{{RelationTable/GetFirstAuthor|Reference:Granstrom_E:Samuelsson_B:,J. Biol. Chem.,1971,246,5254}}]].
|Chemical Synthesis=
|Metabolism=
|Symbol=PGFalpha-MUM
}}

{{Lipid/Footer}}